Investment Rating - The report maintains a "Neutral" rating for the company with a target price raised from HKD 7.00 to HKD 7.40, reflecting a potential upside of 4.1% based on a target P/E ratio of 10.0 times FY26 earnings [4][7]. Core Insights - The company's FY25 interim results are broadly in line with expectations, with a 15.6% year-on-year increase in net profit attributable to shareholders, reaching RMB 560 million. This growth is attributed to a 9.9% increase in total revenue to RMB 12.61 billion, driven by a 22.2% increase in the clean energy segment [1][4]. - New order intake for H1 2025 decreased by 34.5% year-on-year to RMB 10.74 billion, with the clean energy segment seeing a 30.6% decline. However, the company anticipates a rebound in new orders in the second half of the year [2][4]. - The company is transitioning from a "key equipment + core process" service provider in clean energy to a "comprehensive service provider," which is expected to enhance sustainable profit growth [3]. Financial Summary - For FY25, the company forecasts a 3.3% reduction in net profit due to the decline in new orders, but anticipates continued cost control measures will lead to a 0.9% increase in FY26 profit projections. Additionally, FY27 projections have been introduced [4][6]. - Key financial metrics include: - Revenue growth rates: 20.5% in 2023, 4.8% in 2024, and projected 4.1% in 2025 [6][12]. - Net profit attributable to shareholders is projected to grow from RMB 1,114 million in 2023 to RMB 1,203 million in 2025, reflecting a 9.8% increase [6][12]. - The company maintains a healthy order backlog, with total orders slightly down by 0.6% year-on-year to RMB 29.18 billion as of June 30, 2026, while the clean energy segment's backlog grew by 9.9% [2][4].

交银国际研究 财务模型更新 | 医药 | 收盘价 | | 目标价 | | 潜在涨幅 | 2025 年 8 月 28 日 | | --- | --- | --- | --- | --- | --- | --- | | 港元 | | 66.50 | 港元 | 78.00↑ | +17.3% | | | 康诺亚 (2162 HK) | | | | | | | 1H25 核心品种市场渗透加速，差异化布局，上调目标价 司普奇拜单抗首个完整半年商业化成绩优异，TSLP/IL-13 双抗有望成为自免领 域下一代重磅单品，重点布局鼻科适应症。借助强大的临床开发执行力及差 异化显著的多种技术平台，公司跨技术路径、跨疾病领域的多元产品矩阵逐 步成型，并从自免和肿瘤进一步延展至更多大潜力治疗领域。上调目标价。 个股评级 买入 1 年股价表现 资料来源 : FactSet 8/24 12/24 4/25 8/25 -20% 0% 20% 40% 60% 80% 100% 120% 140% 2162 HK 恒生指数 股份资料 | 52周高位 (港元) | 74.75 | | --- | --- | | 52周低位 (港元) | 27 ...

Investment Rating - The report maintains a "Buy" rating for the company, considering the profit growth driven by investment returns and the positive shift in free cash flow [4]. Core Insights - The company's revenue for H1 2025 was 3.086 billion CNY, showing a year-over-year decline of 1.55%, while the net profit attributable to shareholders reached 1.286 billion CNY, reflecting a year-over-year increase of 9.33%, slightly exceeding expectations [4]. - The profit growth is primarily attributed to the increased contributions from joint ventures, particularly from Conch Cement, which contributed 839 million CNY, a year-over-year increase of 19.72% [4]. - The company has confirmed a cash flow turning point, with operating cash flow at 915 million CNY, slightly down year-over-year, but free cash flow turned positive at 366 million CNY, leading to the announcement of an interim dividend of 0.10 HKD per share [4]. Financial Data and Profit Forecast - Revenue projections show a decline from 8,015 million CNY in 2023 to 5,580 million CNY by 2027, with corresponding year-over-year growth rates of 2%, -22%, -2%, -4%, and -5% [3][5]. - Net profit is expected to increase from 2,464 million CNY in 2023 to 2,540 million CNY in 2027, with year-over-year growth rates of -18%, 16%, 4%, and 4% [3][5]. - Earnings per share are projected to rise from 1.37 CNY in 2023 to 1.42 CNY in 2027, with a price-to-earnings ratio decreasing from 7.2 to 7.0 over the same period [3][5].

Investment Rating - The investment rating for the company is "Buy" and is maintained [7]. Core Views - The company has shown a quarter-on-quarter improvement in profitability, with a focus on expanding and extending its share buyback program. Despite potential short-term performance pressure due to industry downturns, the company is expected to outperform the industry, especially if significant policies are implemented [2][4]. Summary by Sections Financial Performance - In Q2 2025, the company achieved revenue of 26 billion yuan (up 11.3%), with a net profit attributable to shareholders of 1.3 billion yuan (down 31.2%). Adjusted net profit was 1.8 billion yuan (down 32.4%). For H1 2025, these figures were 49.3 billion yuan, 2.2 billion yuan, and 3.2 billion yuan respectively, with year-on-year changes of +24.1%, -7.2%, and -21.3% [4]. Business Operations - The self-operated platform has driven GTV growth, with both Lianjia and Beilian's existing housing monetization ratios improving for two consecutive quarters. The profitability of existing homes, new homes, and rental businesses has improved quarter-on-quarter, while the home decoration business has achieved profitability at the city level. Effective fee management has significantly enhanced potential profit elasticity [2][4]. Shareholder Returns - The company has emphasized shareholder returns by increasing and extending its share buyback program. In H1 2025, it spent 394 million USD on share repurchases, buying back nearly 1.7% of the total shares issued at the end of 2024. The buyback authorization has been increased from 3 billion USD to 5 billion USD, with the program extended until August 31, 2028 [4]. Future Outlook - The company is expected to maintain a valuation premium due to its competitive advantages, relative scarcity, and potential earnings elasticity. The adjusted net profit forecasts for 2025-2027 are 6.63 billion, 7.18 billion, and 7.53 billion yuan, with corresponding PE ratios of 23.2, 21.4, and 20.4 [4].

交银国际研究 财务模型更新 | 电池 | 收盘价 | | 目标价 | | 潜在涨幅 | 2025 年 8 月 28 日 | | --- | --- | --- | --- | --- | --- | --- | | 港元 | | 21.60 | 港元 | 24.77 | +14.7% | | | 中创新航 (3931 HK) | | | | | | | 1H25 盈利能力稳步提升，海外储能和商用车业务迎来突破；维持买入 我们调整了中创新航 （3931 HK） 的盈利预测，基于 DCF 模型，维持目标价 24.77 港元。我们看好海外储能和商用车业务突破后带动电池出货量增长，同 时公司盈利能力稳步提升，维持买入。 angus.chan@bocomgroup.com (86) 21 6065 3601 盈利预测变动 | | | ———— 2025E ———— | | | ———— 2026E ———— | | | ———— 2027E ———— | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | (人民币百万) | 新预测 | 前 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company achieved a revenue growth of 15.3% year-on-year in H1 2025, driven by increased procurement from core clients and enhanced operational efficiency [7] - The company reported a gross profit of 4.058 billion RMB in H1 2025, with a gross margin of 27.1%, reflecting a slight decrease due to rising labor costs [7] - The company maintains a strong dividend payout ratio of approximately 60% [7] - The company has a clear long-term strategy focusing on market expansion, capacity optimization, and institutional improvement amidst external disruptions and intensified industry competition [7] - The company is positioned as a leading player in the sports apparel manufacturing sector, benefiting from strong client relationships and mature production technology [7] Financial Summary - Revenue projections for the company are as follows: 24,995.68 million RMB in 2023, 28,662.94 million RMB in 2024, 31,906.94 million RMB in 2025, 35,266.51 million RMB in 2026, and 38,918.06 million RMB in 2027, with respective growth rates of -10.14%, 14.67%, 11.32%, 10.53%, and 10.35% [6] - The net profit attributable to the parent company is projected to be 4,557.26 million RMB in 2023, 6,240.58 million RMB in 2024, 6,612.20 million RMB in 2025, 7,335.75 million RMB in 2026, and 8,108.96 million RMB in 2027, with growth rates of -0.12%, 36.94%, 5.95%, 10.94%, and 10.54% respectively [6] - The company’s earnings per share are expected to increase from 3.03 RMB in 2023 to 5.39 RMB in 2027 [6] - The return on equity (ROE) is projected to be 13.87% in 2023, increasing to 18.16% by 2027 [6]

Investment Rating - The report assigns a rating of "Outperform" for Shenzhou International, indicating an expected total return over the next 12-18 months that exceeds the return of its relevant broad market benchmark [19]. Core Insights - Order growth exceeded market expectations, with revenue for the first half of 2025 reaching RMB 14.966 billion, a year-on-year increase of 15.3%, primarily driven by volume growth [2][7]. - Gross profit was RMB 4.058 billion, up 7.9% year-on-year, but gross margin decreased by 1.9 percentage points to 27.1% due to rising labor costs, increased raw material and freight costs, and inefficiencies in newly commissioned factories [2][7]. - Net profit attributable to shareholders rose 8.4% year-on-year to RMB 3.177 billion, with a net margin of 21.2%, down 1.4 percentage points year-on-year [2][7]. - The interim dividend was HKD 1.38 per share, reflecting a 10.4% increase year-on-year, with a maintained payout ratio of 60% [2][7]. Customer Structure and Performance - The four core customers accounted for 82.1% of revenue, an increase of 2.6 percentage points year-on-year, with significant order growth from Uniqlo and Adidas at nearly 30% year-on-year [2][8]. - Nike's orders increased by mid-single digits, while Puma's orders grew by mid-teens year-on-year, indicating stable relationships with core clients [2][8]. - New clients such as Polo and Lacoste also showed strong order growth, demonstrating the company's capability in client development [2][8]. Regional and Product Performance - Sportswear revenue increased by 9.9% year-on-year to RMB 10.129 billion, while casual wear surged by 37.4% year-on-year to RMB 3.792 billion, driven by overseas demand recovery [3][9]. - The U.S. market saw the most significant growth, with revenue up 35.8% year-on-year to RMB 2.555 billion, while domestic sales in China fell by 2.1% year-on-year to RMB 3.646 billion due to weak demand for sports products [3][9]. Capacity Expansion and Future Outlook - The company is expanding capacity through multiple initiatives, including a new fabric plant in Vietnam and a garment plant in Cambodia, with a total capital expenditure of RMB 1.53 billion in the first half of 2025 [4][10]. - Management expects stable orders for the full year, with limited impact from tariffs, as the company focuses on high-value-added products to maintain leading gross margins [4][11].

Investment Rating - The report maintains a "Buy" rating for H&H International Holdings (1112.HK) [1][4] Core Views - The company's performance in the first half of 2025 met previous forecasts, with revenue of HKD 7.02 billion, a year-on-year increase of 4.9% [4] - The report highlights the continuous market share growth of the company's infant formula brand, with a significant increase in the ultra-premium segment in mainland China [4] - The report projects total revenue for 2025-2027 to be HKD 14.37 billion, HKD 15.49 billion, and HKD 16.44 billion respectively, with net profit estimates of HKD 676 million, HKD 845.5 million, and HKD 952.9 million [1][4] Revenue and Profit Analysis - In the first half of 2025, the revenue from the ANC (Adult Nutrition and Care) business was HKD 3.44 billion, up 5.0% year-on-year, with mainland China contributing HKD 4.94 billion, a growth of 8.7% [4] - The BNC (Baby Nutrition and Care) segment achieved revenue of HKD 2.50 billion, a 2.9% increase, with a notable 10.0% growth in mainland China [4] - The PNC (Pet Nutrition and Care) business reported revenue of HKD 1.08 billion, reflecting a 9.6% increase, driven by a successful high-end strategy [4] Financial Forecasts - The report forecasts total revenue for 2024A at HKD 13.05 billion, with a projected growth rate of -6.3% [5] - The estimated diluted earnings per share for 2025E is HKD 1.05, with a P/E ratio of 13.27 based on the current price [5] - The report maintains the target price at HKD 16.9, indicating potential upside from the current market price [4][5]

Investment Rating - The report assigns a "Buy" rating to COFCO Joycome (1610.HK) with a target price of HKD 2.4 per share, indicating a potential upside of 29% from the current price of HKD 1.86 [1][6][16]. Core Views - The company has turned a profit in H1 2025, driven by strong performance in pig farming and fresh meat businesses. The revenue for H1 2025 reached HKD 89.63 billion, a year-on-year increase of 19.8%, primarily due to stable production and improved efficiency in the farming sector [3][4][8]. - The report highlights significant growth in various business segments, with pig farming revenue increasing by 116.58% year-on-year, and fresh meat sales rising by 25.1% [4][6][8]. - The company is expected to continue benefiting from cost optimization in pig farming, which will contribute to profit margins, alongside an increase in brand revenue share that is anticipated to enhance profitability in the fresh meat segment [6][16]. Summary by Sections Financial Performance - In H1 2025, the company reported a profit attributable to shareholders of HKD 1.98 billion, recovering from a loss of HKD 3.22 billion in the same period last year. The gross margin before fair value adjustments for biological assets was 8.2%, up 7.2 percentage points year-on-year [4][8]. - The company achieved a pig output of 2.898 million heads, a year-on-year increase of 83.0%, while the average selling price for pigs decreased by 4.5% to HKD 14.59 per kilogram [4][9]. Business Segments - The fresh pork sales volume reached 150,000 tons, up 25.1% year-on-year, with branded boxed pork sales increasing by 46.5% to 27.792 million boxes. The revenue share from branded products in the fresh pork business rose to 31.2%, an increase of 4.5 percentage points from the previous year [6][13]. - The company is focusing on differentiated products, such as flaxseed pork, which has gained recognition in the market, enhancing its brand visibility through strategic channel partnerships [6][13]. Future Outlook - The report forecasts that the company's net profit attributable to shareholders will be HKD 5.02 billion, HKD 7.47 billion, and HKD 9.56 billion for the years 2025 to 2027, respectively [6][16].

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Insights - The company achieved a revenue of 25.1 billion RMB in the first half of 2025, representing a year-on-year growth of 14%, and a net profit attributable to shareholders of 1.09 billion RMB, up 8% year-on-year [1] - The company distributed an interim dividend of 0.03 HKD per share, to be paid to shareholders by October 31, 2025 [1] - The company ranked 9th in sales with a contract sales amount of 53.35 billion RMB in the first half of 2025, a 20% increase from 44.54 billion RMB in the same period of 2024, marking its first entry into the top ten of the industry [1] - The company has focused on quality-driven sales growth and organizational transformation, leading to improved operational efficiency and reduced financing costs [1][2] Summary by Sections Financial Performance - For the first half of 2025, the company reported management expenses of 1.22 billion RMB, down from 1.29 billion RMB in the same period of 2024, resulting in a management expense ratio of 4.8%, down from 5.8% [2] - Sales expenses were reported at 830 million RMB, down from 980 million RMB in the previous year, with a sales expense ratio of 3.3%, down from 4.5% [2] Financing and Debt - As of June 30, 2025, the company had interest-bearing debt of approximately 123.3 billion RMB, a decrease of 4.7% year-on-year, with short-term debt accounting for 22.3% [3] - The total interest expense was approximately 3.26 billion RMB, down from 3.55 billion RMB in the same period of 2024 [3] Profit Forecast and Valuation - The company has revised its net profit forecasts for 2025-2027 to 1.22 billion RMB, 1.33 billion RMB, and 1.46 billion RMB respectively, up from previous estimates [3] - The current stock price corresponds to a price-to-earnings (P/E) ratio of 14.6, 13.4, and 12.2 for 2025-2027 [3]